Fujita Health University Hospital

www.fujita-hu.ac.jp
Nagoya, Japan
SEARCH FILTERS
Time filter
Source Type

News Article | April 17, 2017
Site: www.bbc.co.uk

Toyota will be renting out robotic leg braces to 100 Japanese medical centres from autumn this year. The Welwalk WW-1000 system is designed for people with severe mobility loss in one leg, such as stroke patients. The motorised brace fits around the knee and lower leg, helping the wearer to bend and straighten the joint. Experts say that being able to rent the equipment should make it more affordable for medical facilities than buying it outright. The system will cost one million yen ($9,130; £7,298) up front, with a monthly fee of 350,000 yen ($3,195; £2,554). Toyota has not released details of how much it would cost if it were available to buy rather than rent. It was developed in conjunction with Fujita Health University Hospital. Patients first learn to use the device by walking on a special treadmill that monitors their gait, with their weight supported from above by a harness. One of Toyota's chief research officers, Toshiyuki Isobe, said this approach helped "to reduce the burden on the patient and allows them to engage in training for longer." As users continue their rehabilitation, sensors in the brace monitor how they are walking, adjusting the amount of support it provides. Dr Eiichi Saito, executive vice president of Fujita Health University, said the aim was to provide "just enough assistance", gradually reducing it so that patients learned to walk better on their own. But as Dr Farshid Amirabdollahian, an expert in rehabilitation robotics and assistive technology at the University of Hertfordshire, explained, such technology is not new. "A system called Lokomat, which works on both legs, has been adopted by the NHS," he said. "There are similar systems in use in the Netherlands and the United States." These walking assist systems provide support for both legs, as this can help train the user to balance their weight and movement. "What is interesting here is the service model," he continued. "Previously users of this technology were limited by how much they could afford: rehabilitation technology is quite expensive and many [hospitals] cannot afford it." He said that Toyota's decision to allow facilities to rent the equipment meant more should be able to meet the initial costs and the monthly premiums. Japan is the fastest-aging nation in the world. In 2015 more than a quarter of the population was aged 65 or older, compared to the global average of 8.5%. As the number of elderly people requiring care and assistance increases, the number of working-age people able to provide those services is decreasing. That has prompted Japanese companies to develop mobility assistance devices aimed at improving the wellbeing and independence of the elderly and reducing the burden on their caregivers. In 2015, Honda launched a rental service for its own walking assistance system. Unlike Toyota's mobility aid, it fits around the wearer's waist and thighs and works to improve their stride.


Patent
Fujita Health University Hospital and The Research Foundation For Microbial Diseases Of | Date: 2016-02-05

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.


Patent
University of Miyazaki, Fujita Health University Hospital and Perseus Inc. | Date: 2016-07-13

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.


Patent
University of Miyazaki, Fujita Health University Hospital and Perseus Inc. | Date: 2014-09-05

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.


Patent
Fujita Health University Hospital, Osaka University and Perseus Inc. | Date: 2016-06-29

It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).


Patent
Fujita Health University Hospital, Osaka University and Perseus Inc. | Date: 2014-08-20

It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).


Patent
Fujita Health University Hospital | Date: 2016-01-20

An antibody against CD73 obtained by a method comprising: (1) the step of preparing a plural number of antibodies respectively recognizing cell surface antigens; (2) the step of bringing each of these antibodies into contact with a cell of the same species; (3) the step of analyzing each of the cells having been treated in the step (2) by flow cytometry and thus obtaining data indicating the reactivity of each antibody with its cell surface antigen; and (4) the step of comparing the thus obtained data.


Patent
Fujita Health University Hospital | Date: 2016-06-29

Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type A influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the VH1-69 gene in a biological sample originating from a subject.


The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.


Patent
Fujita Health University Hospital | Date: 2014-08-18

Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type A influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the VH1-69 gene in a biological sample originating from a subject.

Loading Fujita Health University Hospital collaborators
Loading Fujita Health University Hospital collaborators